Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Rhinovirus Infections Overview | 6 | 1 |
| Therapeutics Development | 7 | 2 |
| Pipeline Products for Rhinovirus Infections Overview | 7 | 1 |
| Pipeline Products for Rhinovirus Infections Comparative Analysis | 8 | 1 |
| Rhinovirus Infections Therapeutics under Development by Companies | 9 | 1 |
| Rhinovirus Infections Therapeutics under Investigation by Universities/Institutes | 10 | 1 |
| Rhinovirus Infections Pipeline Products Glance | 11 | 2 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Rhinovirus Infections Products under Development by Companies | 13 | 1 |
| Rhinovirus Infections Products under Investigation by Universities/Institutes | 14 | 1 |
| Rhinovirus Infections Companies Involved in Therapeutics Development | 15 | 6 |
| AIMM Therapeutics B.V. | 15 | 1 |
| AstraZeneca Plc | 16 | 1 |
| Aviragen Therapeutics, Inc. | 17 | 1 |
| Biological Mimetics, Inc. | 18 | 1 |
| Boehringer Ingelheim GmbH | 19 | 1 |
| Novartis AG | 20 | 1 |
| Rhinovirus Infections Therapeutics Assessment | 21 | 9 |
| Assessment by Monotherapy Products | 21 | 1 |
| Assessment by Target | 22 | 2 |
| Assessment by Mechanism of Action | 24 | 2 |
| Assessment by Route of Administration | 26 | 2 |
| Assessment by Molecule Type | 28 | 2 |
| Drug Profiles | 30 | 14 |
| BNT-014 Drug Profile | 30 | 2 |
| KR-22809 Drug Profile | 32 | 1 |
| Monoclonal Antibodies to Inhibit Viral 3C Protease for Human Rhinovirus Infections Drug Profile | 33 | 1 |
| Monoclonal Antibody for Human Rhinovirus Infections Drug Profile | 34 | 1 |
| OBR-5340 Drug Profile | 35 | 1 |
| PL-402 Drug Profile | 36 | 1 |
| Polymer for Viral Infections Drug Profile | 37 | 1 |
| Recombinant Peptide for Rhinovirus Infection Drug Profile | 38 | 1 |
| Small Molecule to Inhibit PI4KIII beta for Rhinovirus Infection Drug Profile | 39 | 1 |
| Small Molecules to Inhibit 3C Protease for Rhinovirus Infection Drug Profile | 40 | 1 |
| vapendavir Drug Profile | 41 | 3 |
| Rhinovirus Infections Dormant Projects | 44 | 1 |
| Rhinovirus Infections Product Development Milestones | 45 | 2 |
| Featured News &Press Releases | 45 | 1 |
| Mar 03, 2015: Biota Commences Dosing in Vapendavir SPIRITUS Phase 2b Trial | 45 | 1 |
| Mar 28, 2012: Biota Announces Positive Phase IIb Data In Asthma Patients With Human Rhinovirus Infection | 45 | 2 |
| Appendix | 47 | 2 |
| Methodology | 47 | 1 |
| Coverage | 47 | 1 |
| Secondary Research | 47 | 1 |
| Primary Research | 47 | 1 |
| Expert Panel Validation | 47 | 1 |
| Contact Us | 47 | 1 |
| Disclaimer | 48 | 1 |